Generic Dabigatran for Cancer-Associated Venous Thromboembolism: Real-World Data

Venous thromboembolism (VTE) is common in patients with cancer and is associated with increased mortality. Dabigatran is effective or superior to conventional agents like warfarin or low-mol-wt-heparin (LMWH) for treating cancer-associated thrombosis (CAT). However, there is limited data outside of clinical trials, and concerns exist about the potential side effects in unselected patients.